Biologic markers determine both the risk and the timing of recurrence in breast cancer
暂无分享,去创建一个
Dan H. Moore | Frederick L. Baehner | Andrew N. J. Tutt | Laura J. Esserman | Philip W. Chu | Christina Yau | L. Esserman | A. Tutt | C. Benz | C. Yau | F. Baehner | Philip Chu | John W. Park | C. Gillett | D. Moore | E. Ozanne | Christopher C. Benz | P. Tsing | R. Chung | V. Tandon | Stig Kreps | Elissa Ozanne | Vickram J. Tandon | Pamela J. Tsing | Robert E. Chung | Stig Kreps | Cheryl E. Gillett | D. Moore
[1] I. Ellis,et al. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.
[2] P. Hall,et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[3] Carlos Caldas,et al. A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer , 2008, Breast Cancer Research.
[4] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[5] W. Olszewski,et al. HER2 status in breast cancer determined by IHC and FISH: comparison of the results. , 2004, Polish journal of pathology : official journal of the Polish Society of Pathologists.
[6] C. Sotiriou,et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures , 2007, Breast Cancer Research.
[7] Leo Breiman,et al. Classification and Regression Trees , 1984 .
[8] S. Crossing,et al. Communicating prognosis in early breast cancer: do women understand the language used? , 2000, The Medical journal of Australia.
[9] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[10] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.
[11] J. Bergh,et al. Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series , 2007, Clinical Cancer Research.
[12] Christos Hatzis,et al. Commercialized multigene predictors of clinical outcome for breast cancer. , 2008, The oncologist.
[13] Gianluca Bontempi,et al. Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.
[14] Trevor Hastie,et al. Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature , 2008, BMC Cancer.
[15] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[16] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[17] R. Gray,et al. Annual hazard rates of recurrence for breast cancer after primary therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. J. van de Vijver,et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.
[19] Andy J. Minn,et al. Genes that mediate breast cancer metastasis to lung , 2005, Nature.
[20] Howard Y. Chang,et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[21] Melania Pintilie,et al. Analysing and interpreting competing risk data , 2007, Statistics in medicine.
[22] B. Asselain,et al. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. , 1996, British Journal of Cancer.
[23] E. Perez,et al. Molecularly targeted therapies for breast cancer. , 2005, Cancer control : journal of the Moffitt Cancer Center.
[24] Karen A Gelmon,et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[26] A. Nobel,et al. The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.
[27] Samuel Leung,et al. Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.
[28] J. Thigpen. Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer , 2011 .
[29] C K Osborne,et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Y. Fisher,et al. Comparison of Results , 1995 .
[31] J. Foekens,et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.
[32] Lajos Pusztai,et al. Gene expression profiling of breast cancer , 2009, Breast Cancer Research.
[33] L. Esserman,et al. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer , 2010, Breast Cancer Research.
[34] Jason I. Herschkowitz,et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.
[35] P. Butow,et al. Women’s preferences for discussion of prognosis in early breast cancer , 2001, Health expectations : an international journal of public participation in health care and health policy.
[36] L. V. van't Veer,et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. , 2006, Journal of the National Cancer Institute.
[37] E. Perez,et al. A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer , 2003 .
[38] Carlos Caldas,et al. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the Proliferation, Immune response and RNA splicing modules in breast cancer , 2008, Breast Cancer Research.
[39] I. Ellis,et al. Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.